News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • AppLovin's quarter shows the ad platform still converting new sales into high cash and profit.
  • Shares have plunged, creating a tactical long opportunity.
  • Firm projects 55% revenue growth and 66%+ operating margins by 2026.
  • Valuation sits below 20x projected earnings.
  • Recommended trade: enter near $347, stop at $300, target $520 over the next 180 trading days.
  • Report warns the trade is high-risk and recommends trimming exposure to address legal risk.

Latest Articles

Ten-League International Holdings Limited Reports Unaudited Financial Results for the First Six Months of Fiscal Year 2026

Ten-League International Holdings Limited Reports Unaudited Financial Results for the First Six Months of Fiscal Year 2026

Ten-League International Holdings Limited reported its unaudited financial results for the first six months of fiscal year 2026, showing total revenues of S$33.1 million (US$25.6 million) with a significant shift towards higher-value engineering consultancy services and rental income representing 45.4% of total revenue compared to 18.5% last year. …

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Verrica Pharmaceuticals announced they will present new analysis from Phase 3 trials indicating their FDA-approved drug YCANTH (VP-102) clears molluscum contagiosum lesions approximately four times faster than vehicle, regardless of disease duration. Additional data on investigational drug VP-315 for skin cancer will also be showcased. The clinical…

Cycurion Discusses Record Contract Win, Public Safety Expansion and Growth Strategy in New Interview

Cycurion Discusses Record Contract Win, Public Safety Expansion and Growth Strategy in New Interview

Cycurion, Inc. announced its largest contract award to date, a $54.6 million 10-year engagement supporting the modernization of a major state Health and Human Services system. The company also completed the acquisition of Digital Ally's Video Solutions business, expanding its public safety portfolio and recurring revenue base. CEO L. Kevin Kelly em…

Parabolic Announces $9.3 Million in Annualized Cost Savings from ConnectAndSell Integration and Business Unit Realignment

Parabolic Announces $9.3 Million in Annualized Cost Savings from ConnectAndSell Integration and Business Unit Realignment

Banzai International, Inc. (Parabolic) has executed initiatives following its ConnectAndSell acquisition that are expected to yield approximately $9.3 million in annualized cost savings. These savings come from workforce reductions, minimized third-party contractor use, and the implementation of a new business unit operating model aimed at improvin…

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Celcuity Inc. announced that its drug REVTORPYK (gedatolisib) is now commercially available in the United States for treatment of hormone receptor-positive, HER2-negative advanced breast cancer patients without PIK3CA mutation, following progression on endocrine therapy. REVTORPYK, a first-in-class inhibitor of all class I PI3K isoforms and mTOR co…

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Immutep Limited, a late-stage immunotherapy biotech firm, has received approximately A$856,669 from the Australian Federal Government's R&D tax incentive program for its 2025 fiscal year expenditures. The funding, including additional French and German tax incentives, supports the advancement of its cancer and autoimmune disease therapies, notably …

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced promising 52-week Phase 1b/2a RESOLVE trial results for EP-104GI, showing sustained clinical remission and histologic improvements in patients with Eosinophilic Esophagitis (EoE) after a single dose. The treatment demonstrated favorable safety with no serious adverse events, supporting potential for a once-annual …

TRIO PETROLEUM ANNOUNCES LLOYDMINSTER ACQUISITION WITH CUMMINGS MULTILATERAL OIL WELL AND WORKOVER PRODUCTION GROWTH OPPORTUNITY

TRIO PETROLEUM ANNOUNCES LLOYDMINSTER ACQUISITION WITH CUMMINGS MULTILATERAL OIL WELL AND WORKOVER PRODUCTION GROWTH OPPORTUNITY

Trio Petroleum Corp announced that its Canadian subsidiary acquired 24 oil wells from Marlin Resources in Saskatchewan's Lloydminster region, including 4 producing and 20 shut-in heavy-oil wells. The deal incorporates production of approximately 37 barrels of oil per day with significant upside from a proposed Cummings multilateral well and workove…

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics has dosed the first patient in its global Phase 2/3 clinical trial evaluating SIL204, an RNAi therapeutic for KRAS-mutated locally advanced pancreatic cancer. The study combines direct intratumoral and subcutaneous delivery with standard chemotherapy to improve treatment efficacy. The trial initiated at Tel Aviv Sourasky Medic…

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Esperion Therapeutics, wholly owned by ARCHIMED, is rolling out ENBUMYST, an intranasal bumetanide nasal spray for short-term treatment of edema in heart failure patients. This new administration route offers a non-invasive alternative to IV diuretics and aligns with upcoming CMS Ambulatory Specialty Model payment reforms starting 2027. Esperion ai…

Ichor at a Buyable Dip: A Short-Term Long Trade After a 38% Pullback

Ichor at a Buyable Dip: A Short-Term Long Trade After a 38% Pullback

Ichor Holdings (ICHR) has retraced roughly 38% from earlier highs and now trades near short-term technical support. Recent beats and guidance show revenue momentum and margin expansion, while valuation metrics look reasonable against revenue growth. This is an actionable short-term trade: enter $59.79, stop $56.00, target $75.00 over the next 10 tr…

GM: Defense Wins, ADAS Momentum, and FCF Backstop Make a Lean Long Trade

GM: Defense Wins, ADAS Momentum, and FCF Backstop Make a Lean Long Trade

General Motors sits at an inflection where higher-margin defense contracts and software-enabled services can materially improve enterprise profitability while free cash flow and a modest dividend provide shareholder support. This trade idea proposes a controlled long with a clear entry, stop, and target over a 180 trading day horizon to capture re-…